Lloyd George W., an insider at Royalty Pharma PLC (RPRX), has sold 4,599 shares of the company. The transaction, which took place on November 18, 2025, was executed at a price of $38.28 per share, bringing the total value to approximately $176,000. Following this sale, Lloyd George retains 4,599 shares in the company.
Royalty Pharma, headquartered in New York City, engages in the provision of drug development services. The firm collaborates with innovators from various sectors, including academic institutions and biotechnology companies, to fund innovation in the biopharmaceutical industry. Its portfolio includes royalties on over 35 commercial products, such as Vertex’s Trikafta and GSK’s Trelegy.
As of November 20, 2025, Royalty Pharma has a market capitalization of $22.0 billion and a P/E ratio of 28.81. The company is scheduled to report its upcoming earnings on May 6, 2026, with an estimated EPS of $1.18 and revenue of $754.5 million. Insider transactions, while informative, should be considered within a broader context of company performance and market conditions.